Evaluation of Serum Interleukin-6 Levels in the Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Case-Control Studies
DOI:
https://doi.org/10.3889/oamjms.2019.027Keywords:
Chronic kidney disease, transplantation, serum, cytokine, interleukin-6Abstract
AIM: The purpose of this meta-analysis was the assessment of the serum IL-6 levels in the renal transplant recipients compared to the healthy controls.
MATERIAL AND METHODS: Four databases including PubMed, Web of Science, Scopus, and Cochrane Library were searched up to July 2018 without language restriction. The quality of studies was evaluated using the Newcastle-Ottawa scale (NOS). A continuous random-effects meta-analysis was used by RevMan 5.3 using the mean difference (MD) and 95% confidence intervals (CIs). Also, a regression model was done by Comprehensive Meta-Analysis version 2 (CMA v2).
RESULTS: Out of 615 studies identified in the databases, 15 studies included and analysed in the meta-analysis. The studies were reported from 1994 to 2018. The meta-analysis included 1035 renal transplant recipients and 682 healthy controls. The pooled MD of the serum IL-6 levels in the transplant recipients compared to the healthy controls was 3.25 pg/mL [95%CI: 2.17, 4.32; P < 0.00001; I2 = 98% (P < 0.00001)]. Meta-regression analysis showed that one of the reasons of heterogeneity is the year of publication (Correlation coefficient (r) = 0.208, p-value = 0.00002).
CONCLUSION: An elevated serum IL-6 level in the renal transplant recipients compared to the healthy controls showed that the serum level of this marker could be used for the evaluation of inflammation in ESRD patients undergoing renal transplantation.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1-150.
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovas¬cular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13):1285-95. https://doi.org/10.1056/NEJMoa041365 PMid:15385655 DOI: https://doi.org/10.1056/NEJMoa041365
Eskandari Naji H, Ghorbanihaghjo A, Argani H, Raeisi S, Safa J, Alirezaei AH, et al. Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients. Int J Organ Transplant Med. 2017; 8(2):110-116. PMid:28828171 PMCid:PMC5549008
Palkoci B, Vojtko M, Fialová J, Osinová D, LajÄiaková M. Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience. Int J Organ Transplant Med. 2018; 9(1):1-9. PMid:29531641 PMCid:PMC5839624
Harada KM, Mandia-Sampaio EL, de Sandes-Freitas TV, Felipe CR, Park SI, Pinheiro-Machado PG, et al. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc. 2009; 41(9):3667-70. https://doi.org/10.1016/j.transproceed.2009.04.013 PMid:19917364 DOI: https://doi.org/10.1016/j.transproceed.2009.04.013
Xue D, He X, Zhou C. Serum hepcidin level correlates with hyperlipidemia status in patients following allograft renal transplantation. Transplant Proc. 2014; 46(1):156-9. https://doi.org/10.1016/j.transproceed.2013.06.020 PMid:24507043 DOI: https://doi.org/10.1016/j.transproceed.2013.06.020
Avci Çiçek E, Rota S, Dursun B, Kavalci E. Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients. Ren Fail. 2016; 38(1):35-9. https://doi.org/10.3109/0886022X.2015.1107823 PMid:26627016 DOI: https://doi.org/10.3109/0886022X.2015.1107823
Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, et al. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron. 2002; 92(4):817-23. https://doi.org/10.1159/000065464 PMid:12399626 DOI: https://doi.org/10.1159/000065464
Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis. 2000; 35:611–6. https://doi.org/10.1016/S0272-6386(00)70006-0 DOI: https://doi.org/10.1016/S0272-6386(00)70006-0
Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum. 1992; 35(10): 1197-201. https://doi.org/10.1002/art.1780351012 PMid:1418006 DOI: https://doi.org/10.1002/art.1780351012
Mozaffari HR, Sharifi R, Sadeghi M. Interleukin-6 levels in the serum and saliva of patients with oral lichen planus compared with healthy controls: a meta-analysis study. Cent Eur J Immunol. 2018; 43(1):103-8. https://doi.org/10.5114/ceji.2018.74880 PMid:29731693 PMCid:PMC5927179 DOI: https://doi.org/10.5114/ceji.2018.74880
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7):2461. https://doi.org/10.1182/blood-2002-10-3235 PMid:12433676 DOI: https://doi.org/10.1182/blood-2002-10-3235
Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative stress in patients with chronic kidney disease. Ren Fail. 2015; 37(1):45–9. https://doi.org/10.3109/0886022X.2014.964141 PMid:25375354 DOI: https://doi.org/10.3109/0886022X.2014.964141
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. https://doi.org/10.1016/j.ijsu.2010.02.007 PMid:20171303 DOI: https://doi.org/10.1016/j.ijsu.2010.02.007
Wells GA, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. https://doi.org/10.1002/sim.1186 PMid:12111919 DOI: https://doi.org/10.1002/sim.1186
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc. 2006; 38(10):3434-6. https://doi.org/10.1016/j.transproceed.2006.10.140 PMid:17175295 DOI: https://doi.org/10.1016/j.transproceed.2006.10.140
Malyszko J, Koc-Zorawska E, Malyszko JS, Glowinska I, Mysliwiec M, Macdougall IC. GDF15 is related to anemia and hepcidin in kidney allograft recipients. Nephron Clin Pract. 2013; 123(1-2):112-7. https://doi.org/10.1159/000351810 PMid:23797049 DOI: https://doi.org/10.1159/000351810
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients. Transplant Proc. 2008; 40(10):3470-3. https://doi.org/10.1016/j.transproceed.2008.03.163 PMid:19100415 DOI: https://doi.org/10.1016/j.transproceed.2008.03.163
Colak H, Kilicarslan B, Tekce H, Tanrisev M, Tugmen C, Aktas G, et al. Relationship between epicardial adipose tissue, inflammation and volume markers in hemodialysis and transplant patients. Ther Apher Dial. 2015; 19(1):56-62. https://doi.org/10.1111/1744-9987.12276 PMid:25628169 DOI: https://doi.org/10.1111/1744-9987.12276
Nickerson PW, Rush DN, Jeffery JR, Pochinco D, McKenna RM. High serum levels of interleukin-6 in renal transplant recipients with monoclonal gammopathies. Transplantation. 1994; 58(3):382-6. https://doi.org/10.1097/00007890-199408000-00025 PMid:8053065 DOI: https://doi.org/10.1097/00007890-199408000-00025
Waiser J, Budde K, Katalinic A, Kuerzdörfer M, Riess R, Neumayer HH. Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant. 1997; 12(4):753-9. https://doi.org/10.1093/ndt/12.4.753 PMid:9141007 DOI: https://doi.org/10.1093/ndt/12.4.753
Malan Borel I, Racca A, Garcia MI, Bailat A, Quiroga F, Soutullo A, et al. Gammadelta T cells and interleukin-6 levels could provide information regarding the progression of human renal allograft. Scand J Immunol. 2003; 58(1):99-105. https://doi.org/10.1046/j.1365-3083.2003.01275.x PMid:12828564 DOI: https://doi.org/10.1046/j.1365-3083.2003.01275.x
Lauzurica R, Pastor C, Bayés B, Hernández JM, Romero R. Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. Transplantation. 2005; 80(10):1441-6. https://doi.org/10.1097/01.tp.0000185199.67531.1a PMid:16340789 DOI: https://doi.org/10.1097/01.tp.0000185199.67531.1a
Shaqman M, Ioannidou E, Burleson J, Hull D, Dongari-Bagtzoglou A. Periodontitis and inflammatory markers in transplant recipients. J Periodontol. 2010; 81(5):666-72. https://doi.org/10.1902/jop.2010.090570 PMid:20429646 DOI: https://doi.org/10.1902/jop.2010.090570
Sonkar GK, Singh S, Sonkar SK, Singh U, Singh RG. Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients. Singapore Med J. 2013; 54(9):511-5. https://doi.org/10.11622/smedj.2013174 PMid:24068060 DOI: https://doi.org/10.11622/smedj.2013174
Argani H, Alirezaei A, Ghorbanihaghjo A, Azizi T, Asgharpour M, Bakhtiyari M. Comparing the Serum Levels of Adipocytokines in the Renal Transplant Recipients and Healthy Individuals: A Case-Control Study. Iran Red Crescent Med J. 2018; 20(3):e62674. https://doi.org/10.5812/ircmj.62674 DOI: https://doi.org/10.5812/ircmj.62674
Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006; 8(2):S3. https://doi.org/10.1186/ar1917 PMid:16899107 PMCid:PMC3226076 DOI: https://doi.org/10.1186/ar1917
Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: Pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets. 2009; 8(5):369–82. https://doi.org/10.2174/1871528110908050369 PMid:20025585 DOI: https://doi.org/10.2174/1871528110908050369
Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006; 5:1. https://doi.org/10.1186/1475-2840-5-1 PMid:16412224 PMCid:PMC1352345 DOI: https://doi.org/10.1186/1475-2840-5-1
Gursu M, Celik K, Ozturk S, Turkmen A, Gorcin S, Kocak B, et al. Pentraxin 3 and C-reactive protein as inflammatory markers after a kidney transplant. Exp Clin Transplant. 2014; 12(4):295-9. PMid:24568622
Zimmerman DL, Ruzicka M, Hebert P, Fergusson D, Touyz RM. Short daily versus conventional hemodialysis for hypertensive patients: a randomized cross-over study. PLoS ONE. 2014; 9(5):e97135. https://doi.org/10.1371/journal.pone.0097135 PMid:24875804 PMCid:PMC4038634 DOI: https://doi.org/10.1371/journal.pone.0097135
Cueto-Manzano AM, Morales-Buenrostro LE, González-Espinoza L, González-Tableros N, MartÃn-del-Campo F, Correa-Rotter R, et al. Markers of inflammation before and after renal transplantation. Transplantation. 2005; 80(1):47-51. https://doi.org/10.1097/01.TP.0000164348.16689.03 PMid:16003232 DOI: https://doi.org/10.1097/01.TP.0000164348.16689.03
Stenvinkel P1, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000; 15(7): 953–60. https://doi.org/10.1093/ndt/15.7.953 DOI: https://doi.org/10.1093/ndt/15.7.953
Rumjon A, Sarafidis P, Brincat S, Musto R, Malyszko J, Bansal SS, et al. Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am J Nephrol. 2012; 35(3):295-304. https://doi.org/10.1159/000336528 PMid:22398782 DOI: https://doi.org/10.1159/000336528
Wei JF, Zheng SS. NF-kappa B in allograft rejection. Hepatobiliary Pancreat Dis Int. 2003; 2(2):180-3. PMid:14599965
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Hamidreza Omrani, Sayed Vahid Jasemi, Masoud Sadeghi, Sima Golmohamadi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
